Media Center

News Releases

Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin
October 1, 2015

DUBLIN, IRELAND – October 1, 2015, Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel prescription products for the medical aesthetics market. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion.

KYTHERA® Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss
September 22, 2015

Novel oral treatment could bring new option to large, unsatisfied market  Westlake Village, Calif., September 22, 2015 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for KYTH-105 (setipiprant) for treatment of androgenetic alopecia (AGA), or male pattern hair…

KYTHERA® Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
August 18, 2015

Submission supported by four pivotal Phase III trials conducted in Europe and North America with more than 1,500 patients  Westlake Village, Calif., U.S., August 18, 2015 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced today it has submitted a Marketing Authorization Application (MAA) in the European Union (EU), seeking approval for ATX-101 (deoxycholic acid) injection as…

KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update
August 6, 2015

Company Executing on Commercial Launch of KYBELLA™ (deoxycholic acid) Injection Westlake Village, Calif., Aug. 6, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the second quarter of 2015, and provided an update on recent developments. “We are pleased with the market interest and excitement related to the launch of KYBELLA™, the first…

Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration
August 5, 2015

NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration DUBLIN, IRELAND and WESTLAKE VILLAGE, CALIF. – August 5, 2015 – Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc….

Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA
July 27, 2015

NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA DUBLIN, IRELAND and WESTLAKE VILLAGE, CALIF. – July 27, 2015 – Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc….

KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA™, A Submental Contouring Injectable Drug
July 27, 2015

Recently Launched as KYBELLA™ in the U.S., BELKYRA™ deoxycholic acid Injection Improves Appearance and Profile of Moderate to Severe Submental Fullness or “Double Chin” Westlake Village, Calif., July 27, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it has received authorization from Health Canada to market BELKYRA™ “for improvement in the appearance of moderate…

Allergan to Acquire KYTHERA Biopharmaceuticals
June 17, 2015

NEWS RELEASE CONTACTS: Allergan: Investors:Lisa DeFrancesco (862) 261-7152 Media:David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan to Acquire KYTHERA Biopharmaceuticals – Complements Allergan’s Existing Position in Facial Aesthetics – – Lead Product KYBELLATM the First and Only Approved Non-surgical Treatment for Reduction of Submental Fullness – – Enhances…

KYTHERA Biopharmaceuticals To Present at the Goldman Sachs 36th Annual Global Healthcare Conference
June 3, 2015

Westlake Village, Calif., June 3, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that John Smither, chief financial officer, will present at the Goldman Sachs 36th Annual Global Healthcare Conference. Event:      Goldman Sachs 36th Annual Global Healthcare Conference Date:       Tuesday, June 9, 2015 Time:       2:00 p.m. PT A live…

KYTHERA Biopharmaceuticals To Present at the Bank of America Merrill Lynch 2015 Health Care Conference
May 8, 2015

Westlake Village, Calif., May 8, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference. Event:      Bank of America Merrill Lynch 2015 Health Care Conference Date:       Thursday, May 14, 2015 Time:…